Catalent (2)

Catalent Cell & Gene Therapy is a full-service partner for adeno-associated virus (AAV) vectors and CAR-T immunotherapies, with deep experience in viral vector scale-up and production. Catalent recently acquired MaSTherCell, adding expertise in autologous and allogeneic cell therapy development and manufacturing. Catalent has produced 100+ cGMP batches across 70+ clinical and commercial programs.

Team Members


Dr. Jef Pinxteren

Director of Process and Analytical Development


Maurene Bindels

Senior Business Developer


Jesse Trekker

Business Manager